PATIENT INJECTION RECORD: ADULT SPASTICITY

Patient: ___________________________________________ Chart #: ___________________________________________
Date: ___________________________________________ Time: ___________________________________________

Complete the Dysport Injection Tracker below. For each muscle, indicate the dose used and the specific sites of injection.

**Dysport Injection Tracker**

<table>
<thead>
<tr>
<th>Muscle</th>
<th>Units</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brachialis</td>
<td></td>
<td>Dysport 200-400 Units</td>
</tr>
<tr>
<td>Biceps Brachii</td>
<td></td>
<td>Dysport 200-400 Units</td>
</tr>
<tr>
<td>Pronator Teres</td>
<td></td>
<td>Dysport 100-200 Units</td>
</tr>
<tr>
<td>Flexor Carpi Ulnaris</td>
<td></td>
<td>Dysport 100-200 Units</td>
</tr>
<tr>
<td>Brachioradialis</td>
<td></td>
<td>Dysport 100-200 Units</td>
</tr>
<tr>
<td>Flexor Digitorum Profundus</td>
<td></td>
<td>Dysport 100-200 Units</td>
</tr>
<tr>
<td>Flexor Carpi Radialis</td>
<td></td>
<td>Dysport 100-200 Units</td>
</tr>
<tr>
<td>Flexor Digitorum Superficialis</td>
<td></td>
<td>Dysport 100-200 Units</td>
</tr>
</tbody>
</table>

Complete the Dysport Injection Tracker below. For each muscle, indicate the dose used and the specific sites of injection.

Total Dose: ______________________ Units

Dosing for upper limb spasticity: between 500 Units and 1,000 Units. The maximum recommended total dose per treatment session (upper and lower limb combined) in adults is 1,500 Units.¹

**INDICATIONS**

Dysport® (abobotulinumtoxinA) for injection is indicated for the treatment of:
- Adults with cervical dystonia
- Spasticity in adult patients
- Lower limb spasticity in pediatric patients 2 years of age and older

**IMPORTANT SAFETY INFORMATION**

Warning: Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

To calculate the Dysport FDA-approved dose range for each patient, download the Dysport Dosing Calculator from the Apple App Store and Google Play store. This application is not intended to diagnose, treat, cure, or prevent any disease.

Apple and the App Store are registered trademarks of Apple Inc. Google Play is a registered trademark of Google LLC.

Please see additional Important Safety Information on next page, and accompanying full Prescribing Information, including Boxed Warning and Medication Guide.
**TRACKING AND BILLING: ADULT SPASTICITY**

5 Dysport Units Is 1 Billable Unit

<table>
<thead>
<tr>
<th>Dysport HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0586</td>
<td>Injection, abobotulinumtoxinA, 5 Units</td>
</tr>
</tbody>
</table>

**Dysport Units**

- **Injected Units**
- **Wastage**
- **Billable Units**
- **Total Units**

*Divide by 5 = 1 Billable Unit.

500-Unit vial NDC 15054-0500-1*
Billing Units: 100

300-Unit vial NDC 15054-0530-8*
Billing Units: 60

*Please note that for billing purposes, the NDC number requires 11 digits. Therefore, a zero must be entered into the 10th position (e.g., "15054-0500-01"). This is consistent with the Red Books and First DataBank listings.

**It's Time**

**Dysport HCPCS Code**

J0586 Injection, abobotulinumtoxinA, 5 Units

**It's Time**

**PATIENT INJECTION RECORD: ADULT SPASTICITY**

**Contraindications**

Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow's milk protein, components in the formulation or infection at the injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a reaction occurs, discontinue Dysport and institute appropriate medical therapy immediately.

**IMPORTANT SAFETY INFORMATION (continued)**

**Contraindications**

Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow's milk protein, components in the formulation or infection at the injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a reaction occurs, discontinue Dysport and institute appropriate medical therapy immediately.

Apple and the Apple logo are trademarks of Apple Inc. Google Play is a registered trademark of Google LLC.

To calculate the Dysport FDA-approved dose range for each patient, download the Dysport Dosing Calculator from the Apple App Store and Google Play Store. This application is not intended to diagnose, treat, cure, or prevent any disease.
IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

Dysphagia and Breathing Difficulties
Treatment with Dysport and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant side effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport.

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction
The possibility of an immune reaction when injected intradermally is unknown. The safety of Dysport for the treatment of hyperhidrosis has not been established. Dysport is approved only for intramuscular injection.

Most Common Adverse Reactions

Adults with upper limb spasticity (≥5% and greater than placebo): muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.

Pediatric patients with lower limb spasticity (≥10% and greater than placebo): upper respiratory tract infection, nasopharyngitis, influenza, pharyngitis, cough, and pyrexia.

Drug Interactions
Co-administration of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects, such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport.

Special Populations

Use in Pregnancy
Based on animal data, Dysport may cause fetal harm. There are no adequate and well-controlled studies in pregnant women. Dysport should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use
Based on animal data Dysport may cause atrophy of injected and adjacent muscles; decreased bone growth, length, and mineral content; delayed sexual maturation; and decreased fertility.

Geriatric Use
In general, elderly patients should be observed to evaluate their tolerability of Dysport, due to the greater frequency of concomitant disease and other drug therapy. Subjects aged 65 years and over who were treated with Dysport for lower limb spasticity reported a greater percentage of fall and asthenia as compared to those younger (10% vs. 6% and 4% vs. 2%, respectively).

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Ipsen at 1-855-463-5127. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.